Botulinum toxin B

Drug Profile

Botulinum toxin B

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Torticollis
  • Phase III Sialorrhoea

Most Recent Events

  • 01 Jun 2017 US WorldMeds completes the OPTIMYST trial in Sialorrhoea in Belarus, USA and Ukraine (Intraglandular) (NCT02610868)
  • 22 Apr 2017 Adverse events and efficacy data from a phase III MYSTICOL trial in Sialorrhoea presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Jan 2017 US WorldMeds completes the MYSTICOL trial for Sialorrhoea in USA, Russia and Ukraine (NCT01994109
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top